Clinical augmentation strategies have shown that some improvement in antidepressant efficacy can be achieved by combining the β-adrenergic/serotonin (5-HT)1A/1B receptor antagonist (±)pindolol with a selective serotonin reuptake inhibitor (SSRI). This has lead to the hypothesis that a combination of a 5-HT1A receptor antagonist with an SSRI will lead to a faster onset of antidepressant action. Although there is a significant accumulation of acute preclinical data supporting this rationale, until recently, there have been no investigations examining the chronic effects of combining an SSRI with a 5-HT1A receptor antagonist. Here, we determined the chronic effects of fluoxetine (10 mg/kg o.d.), administered in combination with the selective 5-HT1A receptor antagonist WAY-100635 (1 mg/kg b.i.d.), on serotonergic neurotransmission in the frontal cortex using in-vivo microdialysis. Following chronic administration of fluoxetine ± WAY-100635, functional changes in serotonergic neurotransmission, as well as 5-HT1A autoreceptors, were assessed by administering fluoxetine or (±) 8-hydroxy-2-(di-n-propylamino)tetralin [(±) 8-OH-DPAT] 24 h after the last chronic dose. Chronic administration of WAY-100635 alone produced no detectable change in the functional status of the 5-HT1A receptor. However, fluoxetine alone produced a time-dependent adaptation in serotonergic transmission such that fluoxetine (acutely administered on day 15) was able to produce a two fold increase in extracellular 5-HT levels but the decrease in response to 8-OH-DPAT was completely attenuated. These data indicate that the fluoxetine-induced adaptation was mediated by desensitization of the 5-HT1A receptor. WAY-100635 given chronically in combination with fluoxetine blocked the SSRI-induced desensitization of the 5-HT1A receptor. Furthermore, chronic treatment with this combination produced no tolerance in terms of its ability to acutely increase forebrain 5-HT levels. These data suggest that augmentation of an SSRI by combined pharmacotherapy with a 5-HT1A antagonist would be effective upon prolonged exposure.
Artigas F, Perez V, Alvarez E (1994) Pindolol induces a rapid improvement of patients with depression treated with serotonin reuptake inhibitors. Arch Gen Psychiatry51:248–251
2.
Bel N, Artigas F (1993) Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not raphe nuclei. Synapse15:243–245
3.
Berman R M, Darnell A M, Miller H L, Anand A, Charney D S (1997) Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry154:37–43
4.
Blier P, Bergeron R (1995) Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol15:217–222
5.
Blier P, De Montigny C, Chaput Y (1987) Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol7:24–35
6.
Bosker F J, Van Esseveldt K E, Klompmakers A A, Westenberg H G M (1995) Chronic treatment with fluvoxamine by osmotic minipumps fails to induce persistent functional changes in central 5-HT1A and 5-HT1B receptors, as measured by in vivo microdialysis in dorsal hippocampus of conscious rats. Psychopharmacology117:358–363
7.
Casanovas J P, Hervas I, Artigas F (1999) Postsynaptic 5-HT1A receptors control 5-HT release in the rat medial prefrontal cortex. Neuroreport10:1441–1445
8.
Ceci A, Baschirotto A, Borsini F (1994) The inhibitory effect of 8-OH-DPAT on the firing activity of dorsal raphe serotoninergic neurons in rats is attenuated by lesion of the frontal cortex. Neuropharmacology33:709–713
9.
Chaput Y, Blier P, De Montigny C (1986) Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn-Schmeideberg's Arch Pharmacol333:342–348
10.
Chopin P, Moret C, Briley M (1994) Neuropharmacology of 5-hydroxytryptamine1B/D receptor ligands. Pharmacol Ther62:385–405
11.
Clifford E M, Gartside S E, Umbers V, Cowen P J, Hajos M, Sharp T (1998) Electrophysiological and neurochemical evidence that pindolol has agonist properties at the 5-HT1A autoreceptor in vivo. Br J Pharmacol124:206–212
12.
Czachura J F, Rasmussen K (2000) Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat. Naun-Schmeideberg's Arch Pharmacol362:266–275
13.
Dawson L A, Nguyen H Q (1998) Effects of 5-HT1A receptor antagonists on fluoxetine-induced changes in serotonin in rat frontal cortex. Eur J Pharmacol345:41–46
14.
Dawson L A, Nguyen H Q (2000) The role of 5-HT1A and 5-HT1B/1D receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (±) pindolol. Neuropharmacology39:1044–1052
15.
Dawson L A, Routledge C (1996) Differential effects of potassium channel blockers on extracellular levels of serotonin and dopamine in the striatum of conscious rats. Br J Pharmacol116:3260–3264
16.
Dawson L A, Nguyen H Q, Smith D L, Schechter L E (2000) Effects of chronic fluoxetine treatment, in the presence and absence (±) pindolol: a microdialysis study. Br J Pharmacol130:797–804
17.
Delgado J M R, Charney D S, Price L H, Aghajanian G K, Landis H, Heninger G R (1990) Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant – induced remission by rapid depletion of plasma tryptophan. Arch Gen Pyschiatry47:411–418
18.
Dreshfield L J, Wong D T, Perry, K W, Engleman E A (1996) Enhancement of fluoxetine-dependent serotonin (5-HT) levels by (–) pindolol, an antagonist at 5-HT1A receptors. Neurochem Res21:557–562
19.
Forster E A, Cliffe I A, Bill D J, Dover G M, Jones D, Reilly Y, Fletcher A (1995) A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY100635. Eur J Pharmacol281:81–86
20.
Gardier A M, Le Poul E, Trouvin J H, Chanut E, Desalles M C, Jacquot C (1993) Changes in dopamine metabolism in rat forebrain regions after cessation of long term fluoxetine treatment relationship with brain concentrations of fluoxetine and norfluoxetine. Life Sci54:51–56
21.
Gartside S E, Umbers V, Hajos M, Sharp T (1995) Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol115:1064–1070
22.
Gundlah C, Hjorth S, Auerbach S B (1997) Autoreceptor antagonists enhance the effect of the reuptake inhibitor citalopram on extracellular 5-HT: the effect persists after repeated citalopram treatment. Neuropharmacology36:475–482
23.
Gurling J, Shilliam C, Dourish C T, Routledge C (1994) Elevation of hippocampal 5-HT release in the rat by the selective 5-HT1A receptor antagonist, WAY 100635, is dependent on the phase of the light dark-cycle. In Louilot, A, Durkin T, Spampinato U, Cador M (eds), Monitoring molecules in neuroscience. Proceedings of the 6th International Conference on in vivo methods. Public Typ, Cradignan
24.
Hajos M, Hajos-Korcsok E, Sharp T (1999) Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat. Br J Pharmacol126:1741–1750
25.
Hervas I, Artigas F (1998) Effect of fluoxetine on extracellular 5-hydroxytryptamine in rat brain: role of 5-HT autoreceptors. Eur J Pharmacol358:9–18
26.
Hervas I, Vilaro M T, Mengod G, Artigas F (1999) Modulation of the density and sensitivity of 5-HT1A autoreceptors by prolonged treatment with fluoxetine alone or with WAY100635. Soc Neurosci Abstr24:687.12
27.
Hervas I, Vilaro M T, Romero L, Scorza C M, Mengod G, Artigas F (2001) Desensitization of 5-HT1A autoreceptors by a low chronic fluoxetine dose effect of the concurrent administration of WAY-100635. Neuropsychopharmacology24:11–20
28.
Hjorth S (1993) Serotonin 5-HT1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. J Neurochem60:776–779
29.
Hjorth S (1996) (–) Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine. Eur J Pharmacol303:183–186
30.
Hjorth S, Auerbach S B (1996) 5-HT1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI). Behav Brain Res73:281–283
31.
Hjorth S, Carlsson A (1985) (–)-Pindolol stereospecifically inhibits rat brain serotonin (5-HT) synthesis. Neuropharmacology24:1143–1146
32.
Hjorth S, Carlsson A (1986) Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors?Eur J Pharmacol129:131–138
33.
Hjorth S, Auerbach S B (1994) Lack of 5-HT1A autoreceptor desensitization following chronic citalopram treatment, as determined by in vivo microdialysis. Neuropharmacology33:331–334
34.
Hjorth S, Westlin D, Bengtsson H J (1997) WAY100635-induced augmentation of the 5-HT-elevating action of citalopram: relative importance of the dose of the 5-HT1A (auto) receptor blocker vs. that of the 5-HT reuptake inhibitor. Neuropharmacology36:461–465
35.
Invernizzi R, Bramante M, Samanin R (1994) Chronic treatment with citalopram facilitates the effect of a challenge dose on cortical serotonin output: role of presynaptic 5-HT1A receptors. Eur J Pharmacol260:243–246
36.
Invernizzi R, Bramante M, Samanin R (1996) Role of 5-HT1A receptors in the effects of acute and chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacol Bioch Behav54:143–147
37.
Le Poul E, Laaris N, Doucet E, Laporte AM, Hamon M, Lanfumey L (1995) Early desensitization of somatodendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine. Naunyn-Schmeidebergs Arch Pharmacol352:141–148
38.
Li Q, Muma N A, Van De Kar L D (1996) Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and G(o) proteins and in neuroendocrine responses to a 5-HT1A agonist. J Pharmacol Exp Ther279:1035–1042
39.
Malage I, Trillat A-C, Jacquot C, Gardier A M (1995) Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in vivo microdialysis study. Eur J Pharmacol286:213–217
40.
McAskill R, Mir S, Taylor D (1998) Pindolol augmentation of antidepressant therapy. Br J Psychiatry173:203–208
41.
Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic Press, New York
42.
Raap D K, Evans S, Garcia F, Li Q, Muma N A, Wolf W A, Battaglia G, Van De Kar L D (1999) Daily injections of fluoxetine induce dose-dependent desensitization of hypothalamic 5-HT1A receptors: reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins. J Pharmacol Exp Ther288:98–106
43.
Romero L, Bel N, Artigas F, De Montigny C, Blier P (1996a) Effects of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology15:349–360
44.
Romero L, Ildefonso H, Artigas F (1996b) The 5-HT1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neurosci Letts219:123–126
45.
Rutter J J, Gundlah C, Auerbach S B (1994) Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci Letts171:183–186
46.
Schechter L E, Mcgonigle P, Barrett J E (1999) Serotonergic antidepressants: current and future perspectives. Curr Opin Central Periph Nerv Syst Invest Drugs1:432–447
